tetano
Editor, Senior Moderator
World J Gastroenterol
. 2024 Mar 21;30(11):1480-1487.
doi: 10.3748/wjg.v30.i11.1480. Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
Leonidas Brilakis[SUP] 1 [/SUP], Eirini Theofilogiannakou[SUP] 1 [/SUP], Panagis M Lykoudis[SUP] 1 2 [/SUP]
Affiliations
During the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, particular interest rose regarding the interaction between metabolic dysfunction-associated fatty liver disease (MAFLD) and the COVID-19 infection. Several studies highlighted the fact that individuals with MAFLD had higher probability of severe acute respiratory syndrome coronavirus 2 infection and more severe adverse clinical outcomes. One of the proposed mechanisms is the inflammatory response pathway, especially the one involving cytokines, such as interleukin 6, which appeared particularly elevated in those patients and was deemed responsible for additional insult to the already damaged liver. This should increase our vigilance in terms of early detection, close follow up and early treatment for individuals with MAFLD and COVID-19 infection. In the direction of early diagnosis, biomarkers such as cytokeratin-18 and scoring systems such as Fibrosis-4 index score are proposed. COVID-19 is a newly described entity, expected to be of concern for the years to come, and MAFLD is a condition with an ever-increasing impact. Delineating the interaction between these two entities should be brought into the focus of research. Reducing morbidity and mortality of patients with COVID-19 and MAFLD should be the ultimate objective, and the optimal way to achieve this is by designing evidence-based prevention and treatment policies.
Keywords: COVID-19; Cytokine storm; Drug induced liver injury; Liver fibrosis; Metabolic dysfunction-associated fatty liver disease.
. 2024 Mar 21;30(11):1480-1487.
doi: 10.3748/wjg.v30.i11.1480. Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
Leonidas Brilakis[SUP] 1 [/SUP], Eirini Theofilogiannakou[SUP] 1 [/SUP], Panagis M Lykoudis[SUP] 1 2 [/SUP]
Affiliations
- PMID: 38617460
- PMCID: PMC11008415
- DOI: 10.3748/wjg.v30.i11.1480
During the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, particular interest rose regarding the interaction between metabolic dysfunction-associated fatty liver disease (MAFLD) and the COVID-19 infection. Several studies highlighted the fact that individuals with MAFLD had higher probability of severe acute respiratory syndrome coronavirus 2 infection and more severe adverse clinical outcomes. One of the proposed mechanisms is the inflammatory response pathway, especially the one involving cytokines, such as interleukin 6, which appeared particularly elevated in those patients and was deemed responsible for additional insult to the already damaged liver. This should increase our vigilance in terms of early detection, close follow up and early treatment for individuals with MAFLD and COVID-19 infection. In the direction of early diagnosis, biomarkers such as cytokeratin-18 and scoring systems such as Fibrosis-4 index score are proposed. COVID-19 is a newly described entity, expected to be of concern for the years to come, and MAFLD is a condition with an ever-increasing impact. Delineating the interaction between these two entities should be brought into the focus of research. Reducing morbidity and mortality of patients with COVID-19 and MAFLD should be the ultimate objective, and the optimal way to achieve this is by designing evidence-based prevention and treatment policies.
Keywords: COVID-19; Cytokine storm; Drug induced liver injury; Liver fibrosis; Metabolic dysfunction-associated fatty liver disease.